Related Experiment Video
Updated: May 31, 2026
Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats
Published on: October 24, 2016
Leverage of quick-soluble gelatin microparticles in transarterial chemoembolization of canine urothelial carcinomas
Sunghoon Jeon1, Gahyun Lee1, Jin-Kyung Kim1
1Haemaru Referral Animal Hospital, Seongnam, Republic of Korea.
Abstract:
Lower urinary tract carcinomas in dogs are rare conditions with a poor prognosis. This prospective clinical study evaluated the safety, feasibility, and therapeutic efficacy of transarterial chemoembolization (TACE) using quick-soluble gelatin microparticles (QS-GMP) in 29 client-owned dogs with lower urinary tract carcinomas. Tumors primarily involved the bladder and urethra. Following selective catheterization of tumor-feeding vessels, intra-arterial carboplatin was administered prior to QS-GMP embolization. All patients underwent follow-up computed tomography (CT) scanning 4 weeks post-TACE. Tumor volume decreased in all cases, with a median reduction of 76.41% (95% confidence interval: 65.06-78.41%, p < 0.001). Partial remission was observed in 96.5% of patients; one case showed stable disease. Clinical signs, including pollakiuria, hematuria and stranguria, improved. No major complications occurred during the procedure or within two weeks after the procedure, and minor adverse effects were self-limiting. Repeat TACE was performed in 28/29 patients. The median survival time was 569 days for all patients and 534 days when non-tumor-related deaths were excluded. These findings suggest that TACE with QS-GMP may be an option for dogs with unresectable lower urinary tract carcinomas, with potential for repeated interventions and prolonged survival.
Insights
Transarterial chemoembolization (TACE) using quick-soluble gelatin microparticles (QS-GMP) shows promise for treating canine lower urinary tract carcinomas. This novel approach significantly reduced tumor volume and improved clinical signs, offering a new therapeutic option.
Area of Science:
- Veterinary Oncology
- Interventional Radiology
Background:
- Lower urinary tract carcinomas (LUTCs) in dogs are uncommon and typically have a poor prognosis.
- Current treatment options for unresectable LUTCs are limited.
Purpose of the Study:
- To evaluate the safety, feasibility, and therapeutic efficacy of transarterial chemoembolization (TACE) using quick-soluble gelatin microparticles (QS-GMP) for canine lower urinary tract carcinomas.
Main Methods:
- A prospective clinical study involving 29 client-owned dogs with LUTCs (primarily bladder and urethra).
- Selective catheterization of tumor-feeding vessels followed by intra-arterial carboplatin administration and QS-GMP embolization.
- Follow-up computed tomography (CT) scanning at 4 weeks post-TACE.
Main Results:
- All patients demonstrated tumor volume reduction (median 76.41%, p < 0.001).
- Partial remission was achieved in 96.5% of cases, with significant improvement in clinical signs like pollakiuria and hematuria.
- No major complications were observed; minor adverse effects were self-limiting. Median survival time was 569 days.
Conclusions:
- TACE with QS-GMP is a safe and feasible option for dogs with unresectable lower urinary tract carcinomas.
- This treatment can lead to significant tumor volume reduction, clinical improvement, and prolonged survival.
- The potential for repeated interventions makes TACE a promising therapeutic strategy.
